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Colorectal cancer globally affects more than one million new persons each year, and 
kills more than 700.000. Nevertheless, its diagnosis is still largely based on invasive 
tissue sampling and gaps remain in the understanding of its pathogenesis, with 
complex combinations between lifestyle, genetics, epigenetics, chronic inflammation 
(IBD) and microbiota. Untargeted metabolomics is one of the approaches that can be 
used to solve these issues. 
 
To do so, optimized and validated (NIST SRM 1950) comprehensive GC×GC-
(HR)TOFMS and newly developed GC-MS Orbitrap were applied, along with an in-
house QC system based on all study samples aliquots and control charts to 
guarantee high-quality data. 
 
Practically, replicates of 48 serum samples were analyzed on both platforms: 
samples from patients affected by colorectal cancer (CRC, n = 12), by colorectal 
cancer in remission (R-CRC, n = 12), and samples from healthy patients matched for 
as many biases as possible (HC and R-HC, both n = 12). The aim was to highlight 
candidate biomarkers able to discriminate between matched HC and CRC or R-CRC.   
 
Each technique was investigated in terms of peak capacity, stability, with a 
consideration for the effect of the QC system, and identification power. The results 
were analyzed through their respective specificities, especially the trade between 
mass resolution power and chromatographic separation capacity.  
 
The discrimination potential of the candidate biomarkers was assessed using 
supervised and unsupervised models (PLS & OPLS / PCA and HCA), discriminant 
analysis and ROC curves, with overfitting of the experimental data avoided by re-
sampling and test validation testing. 
 
They were then identified using full mass spectrum, linear retention indices and exact 
mass, which role was particularly scrutinized. Finally, confident identifications were 
used to study the main metabolic pathways altered in the disease, whether in active 
or in remission state. 
 
 
 
 
 
 
